Field Trip IPO On Tuesday, Field Trip Psychedelics became the third publicly traded psychedelic company with at least a $100 million valuation behind MindMed and COMPASS Pathways. If COMPASS is the tech-enabled psychedelic/mental health delivery company and MindMed has the largest psychedelic drug development pipeline, then Field Trip is a bit of both, with clinics as the primary offering at the moment.
Field Trip IPO; MindMed + NYU: News & Events
Field Trip IPO; MindMed + NYU: News & Events
Field Trip IPO; MindMed + NYU: News & Events
Field Trip IPO On Tuesday, Field Trip Psychedelics became the third publicly traded psychedelic company with at least a $100 million valuation behind MindMed and COMPASS Pathways. If COMPASS is the tech-enabled psychedelic/mental health delivery company and MindMed has the largest psychedelic drug development pipeline, then Field Trip is a bit of both, with clinics as the primary offering at the moment.